Chest Medicine (all articles)
Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.
12 Jul, 2021 | 03:08h | UTCPfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN
See also: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP AND Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation AND Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post AND Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press AND Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (a few articles per month are free) AND Question open on need for COVID booster shot, data awaited, WHO says – Reuters
Understanding the Host in the Management of Pneumonia. An Official American Thoracic Society Workshop Report.
12 Jul, 2021 | 01:41h | UTC
RCT: CoronaVac showed efficacy of 83.5% for preventing symptomatic SARS-CoV-2 infection.
9 Jul, 2021 | 10:22h | UTCInvited commentary: CoronaVac: more data for regulators and policy makers
Commentary on Twitter
NEW—Interim analysis from phase 3 trial suggests efficacy of 2 doses of #CoronaVac is 83.5% against symptomatic #COVID19. More research is needed to confirm efficacy in the long term, in a more diverse group, and against emerging #variants of concern.
? https://t.co/TN5b6wwclc pic.twitter.com/4zOvJFIIOH
— The Lancet (@TheLancet) July 8, 2021
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
9 Jul, 2021 | 10:16h | UTCReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization – Nature
Commentaries: Study highlights need for full Covid vaccination to protect against Delta variant – STAT AND How does the Delta variant dodge the immune system? Scientists find clues. – The New York Times
Commentary on Twitter (thread – click for more)
Just published @Nature
Delta variant protection by mRNA and AZ vaccines requires 2-doses, little neutralizing antibody (nAb) with 1-dose, and insufficient nAb with prior covidhttps://t.co/TOgJdMe0g6 pic.twitter.com/KWLb9rBZ44— Eric Topol (@EricTopol) July 8, 2021
CDC: Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients – “Continued use of mRNA COVID-19 vaccines in all recommended age groups will prevent morbidity and mortality from COVID-19 that far exceed the number of cases of myocarditis expected”.
9 Jul, 2021 | 10:17h | UTC
Commentary on Twitter
In a new @CDCMMWR, the Advisory Committee on Immunization Practices recommends everyone 12 & older get a #COVID19 vaccine. The benefits of vaccination in preventing illness & death outweigh the rare risk of heart inflammation after vaccination. More: https://t.co/iPjbhU5jeV. pic.twitter.com/IggrZ4DX7L
— CDC (@CDCgov) July 6, 2021
After the pandemic: perspectives on the future trajectory of COVID-19.
9 Jul, 2021 | 10:18h | UTCAfter the pandemic: perspectives on the future trajectory of COVID-19 – Nature
Will COVID become a disease of the young? – “A growing share of infections among unvaccinated youths in countries with high vaccination rates is putting the spotlight on the role of young people in the pandemic”.
9 Jul, 2021 | 10:14h | UTCWill COVID become a disease of the young? – Nature
2021 ACR Guideline for the Management of ANCA–Associated Vasculitis.
9 Jul, 2021 | 10:09h | UTC
Case series: therapeutic plasma exchange in 3 patients with vaccine-induced immune thrombotic thrombocytopenia.
8 Jul, 2021 | 09:17h | UTC
Commentary on Twitter
Three patients with severe manifestations of VITT after #COVID19 vaccination had poor response to initial therapy with anticoagulants and intravenous immune globulin. Their condition improved after therapeutic plasma exchange was initiated.
— NEJM (@NEJM) July 7, 2021
Prospective national cohort in Chile showed CoronaVac effectiveness was 65.9% for symptomatic Covid-19, 87.5% for hospitalization, 90.3% for ICU admission, and 86.3% for death.
8 Jul, 2021 | 09:22h | UTCEffectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile – New England Journal of Medicine
Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. AND WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.
Commentary on Twitter
Chile's data on Sinovac CoronaVac in NEJM: not controlled study. Model details pic 2
– doses 28 days apart (like Serrana trial)
– symptomatic disease 65.9% (65-67)
– hospitalization 87.5% (87-88)
– intensive care 90.3% (89-91)
– Covid death 86.3% (85-88)
https://t.co/CB1U8Ar163 pic.twitter.com/4HwASRCnwQ— Hilda Bastian, PhD (@hildabast) July 7, 2021
Mounting evidence suggests Sputnik COVID vaccine is safe and effective.
8 Jul, 2021 | 09:14h | UTCMounting evidence suggests Sputnik COVID vaccine is safe and effective – Nature
Perspective | Should People With Immune Problems Get Third Vaccine Doses?
8 Jul, 2021 | 09:07h | UTCShould People With Immune Problems Get Third Vaccine Doses? – The New York Times (a few articles per month are free)
Related: [Preprint] 3rd AstraZeneca shot gives strong immunity. AND Case series: Safety and immunogenicity of a third dose of SARS-CoV-2 vaccine in solid organ transplant recipients.
Review: Non-invasive ventilatory support and high-flow nasal oxygen as first-line treatment of acute hypoxemic respiratory failure and ARDS.
8 Jul, 2021 | 09:01h | UTC
Commentary on Twitter
Physiology-to-bedside overview about non-invasive ventilatory support in AHRF & #ARDS
➡️spontaneous breathing: benefits/harms
➡️how to make spontaneous effort non‑injurious?
➡️optimizing HFNO & NIV
➡️monitoring to detect failure & be protective
➡️evidencehttps://t.co/KPW2u8akhA pic.twitter.com/yKVxrYaFmZ— Intens Care Med (@yourICM) July 7, 2021
M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”.
7 Jul, 2021 | 09:02h | UTCEditorial: IL-6 Receptor Antagonist Therapy for Patients Hospitalized for COVID-19: Who, When, and How? – JAMA
Commentaries: Interleukin-6 antagonists improve outcomes in hospitalised COVID-19 patients – King’s College London AND WHO advises 2 monoclonal antibodies for severe COVID – CIDRAP
Commentary on Twitter (thread – click for more)
1/n
Here we go –
Our paper assessing the role of interleukin-6 antagonists treatments in the management of COVID-19 patients?https://t.co/AJErHypx9a@WHO @jonathanasterne @diazjv @JAMA_current @KCLImmunoMicro @GSTT_ICU @GSTTresearch— Manu Shankar-Hari (@msh_manu) July 6, 2021
A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19.
7 Jul, 2021 | 09:03h | UTCA living WHO guideline on drugs for covid-19 – The BMJ
Commentary on Twitter
The latest version of this @WHO living guidance provides a strong recommendation for interleukin-6 (IL-6) receptor blockers (tocilizumab or sarilumab) in patients with severe or critical covid-19. Read the updated WHO guideline on drugs for #COVID19 https://t.co/FUb9yzFRwo
— The BMJ (@bmj_latest) July 6, 2021
WHO recommends life-saving interleukin-6 receptor blockers for COVID-19 and urges producers to join efforts to rapidly increase access – “These are the first drugs found to be effective against COVID-19 since corticosteroids were recommended by WHO in September 2020”.
7 Jul, 2021 | 09:00h | UTC
Commentary on Twitter (thread – click for more)
? treatment recommendation from WHO:
WHO recommends life-saving interleukin-6 receptor blockers to treat #COVID19 and urges producers to join efforts to rapidly increase access.?https://t.co/h4IcZad2VA pic.twitter.com/YXPkuBVwY4
— World Health Organization (WHO) (@WHO) July 6, 2021
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
7 Jul, 2021 | 08:52h | UTC
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
6 Jul, 2021 | 10:16h | UTCCommentary: Ivermectin: balance of evidence shows no significant benefit against Covid-19 – MSN News
Related: Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”. AND Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”. AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
Choosing Wisely for COVID-19: ten evidence-based recommendations for patients and physicians.
6 Jul, 2021 | 10:21h | UTC
Joint COVAX Statement on the Equal Recognition of Vaccines – COVAX urges all government authorities to recognize as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by WHO.
5 Jul, 2021 | 02:39h | UTCJoint COVAX Statement on the Equal Recognition of Vaccines – World Health Organization
Commentary on Twitter (thread – click for more)
#COVAX urges all government authorities to recognize as fully vaccinated all who have received #COVID19 vaccines approved by WHO or one of 11 approved Stringent Regulatory Authorities, when making decisions on who is able to travel or attend events.
?https://t.co/udYVrYTdMg pic.twitter.com/DihCPUmS8F
— World Health Organization (WHO) (@WHO) July 1, 2021
CDC Report: Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021.
5 Jul, 2021 | 02:40h | UTC
Commentary on Twitter
A new report finds that obesity, diabetes with complication, and the presence of multiple chronic conditions were the strongest chronic risk factors for death from #COVID19 among hospitalized adults. Learn more: https://t.co/KzsarYhHYA. pic.twitter.com/c0vd8ANqa0
— CDC (@CDCgov) July 1, 2021
Opinion | Covid is a greater risk to young people than the vaccines.
5 Jul, 2021 | 02:34h | UTCCovid Is a Greater Risk to Young People Than the Vaccines – The New York Times
Counterpoint: Weighing myocarditis cases, ACIP failed to balance the harms vs benefits of 2nd doses – by Wesley Pegden AND Vaccine-Induced Myocarditis Concerns Demand Respect, Not Absolutism – Medscape (free registration required)
Commentary on Twitter
“Realize the choice is not ‘vaccinate or do nothing.’ It’s ‘vaccinate or eventually contract the coronavirus,’ and the risks that come with it.”
My latest with @celinegounder and @EMDocinTraining@NYTOpinion @acsifferlin https://t.co/wGugCuWgSs
— Jeremy Faust MD MS (ER physician) (@jeremyfaust) July 4, 2021
Roundup on Covid vaccines | A Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark.
5 Jul, 2021 | 02:31h | UTCA Big Hit, A Big Miss, & Mixed Vaccine Schedules: The 18-Month Mark – Absolutely Maybe Blog
Commentary on Twitter
My latest roundup on Covid vax: a big hit, a big miss, & mixed vaccine schedules. 15 vaxes with phase 3 results coming up to the 18-month mark! More than 20 controlled community impact studies now, & lots on immunocompromise | New @PLOS https://t.co/HEsuFc4af3 #IC
— Hilda Bastian, PhD (@hildabast) July 2, 2021
Why Covid-19 outbreaks in countries using Chinese vaccines don’t necessarily mean the shots have failed.
5 Jul, 2021 | 02:30h | UTC
What are the Sinopharm and Sinovac vaccines? And how effective are they? Two experts explain.
5 Jul, 2021 | 02:28h | UTC